Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Immix Biopharma ( (IMMX) ).
On December 7, 2025, Immix Biopharma, Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC for the issuance and sale of over 19 million shares of its common stock and pre-funded warrants. The offering, priced at $5.10 per share, is expected to generate approximately $93.7 million in net proceeds, with the closing anticipated on December 9, 2025. This financial move is part of a strategic effort to bolster the company’s capital, potentially enhancing its market position and operational capabilities.
The most recent analyst rating on (IMMX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Immix Biopharma stock, see the IMMX Stock Forecast page.
More about Immix Biopharma
Immix Biopharma, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative therapies for patients with unmet medical needs.
Average Trading Volume: 576,896
Technical Sentiment Signal: Buy
Current Market Cap: $186.7M
Learn more about IMMX stock on TipRanks’ Stock Analysis page.